In July 2016, the Colombian government enacted Law 1787, which regulates the use of medicinal cannabis and its trade in the country. With this decision and a series of subsequent resolutions, Colombia joined the more than a dozen countries that have put into practice different types of regulation to explore the advantages of this plant as an alternative pharmaceutical.
Is the aim of reducing cannabis cultivation realistic or beneficial for Morocco? What would it actually mean for the major production area the Rif – one of the poorest, most densely populated and environmentally fragile regions in the country? This briefing will give some historical background, discuss developments in the cannabis market, and highlight environmental and social consequences as well as the recent debate about regulation in Morocco and European policies.
Martin Jelsma, Neil Boister, David Bewley-Taylor, Malgosia Fitzmaurice, John Walsh
15 March 2018
Legal tensions are growing within the international drug control regime as increasing numbers of member states move towards or seriously consider legal regulation of the cannabis market for non-medical purposes. Amongst reform options not requiring consensus, inter se modification appears to be the most ‘elegant’ approach and one that provides a useful safety valve for collective action to adjust a treaty regime arguably frozen in time.
In order to better understand the situation around, and possibilities for, local and regional cannabis regulation, a series of six country reports were developed. The country reports provide detailed information about the state of cannabis policy, and the possibilities for change, within each country. This briefing identifies some of the key findings and implications for policy makers and advocates from this research.
Paraguay is the principal producer of cannabis in South America. Despite its importance as a supplier of cannabis in South America, there has been a surprising absence of serious studies of its impact on its own society, and on the play of offer and demand in neighbouring countries.
John Walsh, Martin Jelsma, Tom Blickman, David Bewley-Taylor
19 March 2019
The World Health Organization’s (WHO) Expert Committee on Drug Dependence (ECDD or Expert Committee) released in January 2019 the outcomes of the first-ever critical review of cannabis, recommending a series of changes in the current scheduling of cannabis-related substances under the UN drug control conventions.
Cannabis (or marihuana) is one of the most widely consumed psychoactive substances in the world. According to the United Nations World Drug Report, 183 million people, or 3.8% of the world’s population, used cannabis in 2014. Its cultivation was also reported by 129 countries. Cannabis is subject to the United Nations System for International Control of Narcotic Drugs and Psychotropic Substances (hereafter “drugs”) and is the most widely consumed of all the drugs. According to that control system, cannabis is among the substances with the strictest legal status; they are the most prohibited, supposedly because of the harm they cause and their lack of medical usefulness.
Penggunaan ganja tidak pernah menimbulkan masalah besar di Indonesia, namun kebijakan prohibitionist (pelarangan) tetap diberlakukan sampai sekarang. Meskipun prevalensi konsumsi ganja cukup tinggi, diskusi lokal atau nasional terkait kebijakan ganja jarang sekali dilakukan. Hal ini juga diperburuk oleh sikap anti-narkotika serta kegagalan institusi publik dalam merancang dan menerapkan kebijakan yang berbasis ilmiah. Karena perundang-undangan anti-narkotika yang berlaku saat ini, terdapat banyak hambatan dalam proses penelitian tentang ganja, baik dari segi medis maupun antropologi.